New drug combinations for advanced colorectal cancer after chemotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests two new investigational drugs combined with either another experimental drug or an approved immunotherapy for advanced colorectal cancer that has stopped responding to standard chemotherapy. The goal is to see if these combinations can shrink tumors or slow cancer growth more effectively, and what side effects they may cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic colorectal cancer that has been confirmed by a biopsy or tissue sample.
- You must have already tried at least one line of chemotherapy (a 5-FU based regimen) and your cancer got worse or came back during or shortly after that treatment.
- For the first part of the study, your tumor must be 'wild-type' for RAS and BRAF (meaning no mutations in these genes), and if you have a type of tumor called dMMR/MSI-H, you must have already tried a PD-1 inhibitor and it stopped working.
- It must have been at least 4 weeks (or 5 half-lives of the drug) since major surgery, radiation, or chemotherapy, and any side effects from past treatments must have largely resolved.
- You cannot have had prior treatment with a class of drugs called topoisomerase I inhibitors (like irinotecan), and for Part 1 you cannot have had anti-EGFR antibody therapy (like cetuximab).
- You must not have active hepatitis B or C infections, and you must not have a history of severe eye problems (like keratitis or severe dry eye).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (HLX07, serplulimab, and chemotherapy) for people with advanced squamous non-small cell lung cancer that hasn't been treated before. The goal is to see if this combo works better than the current standard treatments.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy, or just one of those drugs by itself, for people with advanced colorectal cancer that has spread. It aims to see if these treatments can shrink the cancer or help you live longer.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
Hear when a new Colon Cancer Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.